Physician profile
Ashutosh Singh
NPI 1538166376
$1,312.43
in general payments reported to CMS, 2019-2025
18 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.99 · 2021: $95.51 · 2022: $163 · 2023: $253 · 2024: $277 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875 · Education: $84.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.59 |
| Education | $84.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $161.17 | 2023-2025 | Farxiga, Wainua |
| Nxstage Medical, INC. | $129.37 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $123.44 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $122.30 | 2024-2025 | Filspari |
| Novo Nordisk INC | $111.56 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.00 | 2023 | Lifevest |
| Mallinckrodt Enterprises LLC | $94.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.86 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $82.73 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $61.63 | 2024-2025 | |
| Kyowa Kirin, INC. | $55.84 | 2023 | Crysvita |
| Calliditas Therapeutics US INC. | $49.40 | 2025 | Tarpeyo |
| Amgen INC. | $29.50 | 2024 | Krystexxa, Tavneos |
| Ardelyx, INC. | $25.11 | 2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $24.70 | 2025 | Rayaldee |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Vifor Pharma, INC. | $17.26 | 2022 | |
| Daiichi Sankyo INC. | $15.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashutosh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.